Form 4: Tarsus CFO Sells Shares for Tax Obligations

Tarsus Pharmaceuticals' CFO, Jeffrey S. Farrow, sold common stock to cover tax withholding obligations from RSU vesting, not as a discretionary transaction.

Summary

• Jeffrey S. Farrow, Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (TARS), reported the sale of common stock.
• The sales occurred on March 17, 2026, March 18, 2026, and March 19, 2026.
• A total of 2,111 shares were sold on March 17, 2026, at a price of $69.42 per share.
• A total of 2,133 shares were sold on March 18, 2026, at a price of $68.71 per share.
• A total of 2,186 shares were sold on March 19, 2026, at a price of $67.00 per share.
• The transactions were 'sell to cover' sales, mandated by the Issuer to satisfy tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs).
• These sales do not represent discretionary transactions by Mr. Farrow.
• Following these transactions, Mr. Farrow beneficially owns 43,316 shares of Tarsus Pharmaceuticals, Inc. common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sales are non-discretionary and solely for tax purposes, providing no insight into management's confidence or the company's operational performance.

Future Outlook

NA

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and routine practice for executives to satisfy tax obligations upon the vesting of equity awards, such as Restricted Stock Units. These non-discretionary sales are generally not indicative of management's sentiment regarding the company's future prospects or stock performance.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, non-discretionary sales for tax purposes and do not signal a change in management's outlook or company fundamentals.

Key Dates

Recommendation

A seasoned investor or institution would likely maintain a 'hold' recommendation based on this filing. The reported sales by the CFO are non-discretionary 'sell to cover' transactions for tax withholding related to RSU vesting. Such routine events do not reflect management's discretionary view on the stock's future performance and therefore do not provide new fundamental information to warrant a change in investment thesis.

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Jeffrey Farrow